<SEC-DOCUMENT>0001437749-22-017952.txt : 20220728
<SEC-HEADER>0001437749-22-017952.hdr.sgml : 20220728
<ACCEPTANCE-DATETIME>20220728083523
ACCESSION NUMBER:		0001437749-22-017952
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20220728
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220728
DATE AS OF CHANGE:		20220728

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Moleculin Biotech, Inc.
		CENTRAL INDEX KEY:			0001659617
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				474671999
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37758
		FILM NUMBER:		221112943

	BUSINESS ADDRESS:	
		STREET 1:		5300 MEMORIAL DRIVE
		STREET 2:		SUITE 950
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77007
		BUSINESS PHONE:		713-300-5160

	MAIL ADDRESS:	
		STREET 1:		5300 MEMORIAL DRIVE
		STREET 2:		SUITE 950
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77007
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mbrx20220726_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:mbrx="http://www.mbrx.com/20220728"><head>
	<title>mbrx20220726_8k.htm</title>
	<!-- Generated by ThunderDome Portal - 7/28/2022 12:34:10 AM -->
<meta http-equiv="Content-Type" content="text/html" /></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20228K" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20228K" name="dei:EntityCentralIndexKey">0001659617</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="mbrx-20220728.xsd" xlink:type="simple" />
</ix:references>
<ix:resources>
<xbrli:context id="d20228K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2022-07-28</xbrli:startDate>
<xbrli:endDate>2022-07-28</xbrli:endDate>
</xbrli:period>
</xbrli:context>


</ix:resources>
</ix:header>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>WASHINGTON, D.C. 20549</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM <ix:nonNumeric contextRef="d20228K" name="dei:DocumentType"><b>8-K</b></ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CURRENT REPORT</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): <ix:nonNumeric contextRef="d20228K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><b>July 28, 2022</b></ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="logo.jpg" src="logo.jpg" /></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:EntityRegistrantName"><b>MOLECULIN BIOTECH, INC.</b></ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Exact Name of Registrant as Specified in its Charter)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><b>Delaware</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:15.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:EntityFileNumber"><b>001-37758</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:EntityTaxIdentificationNumber"><b>47-4671997</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State or Other Jurisdiction of</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporation or Organization)</div>
			</td>
			<td style="vertical-align:top;width:15.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Commission File No.)</div>
			</td>
			<td style="vertical-align:top;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(I.R.S. Employer Identification</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">No.)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20228K" name="dei:EntityAddressAddressLine1"><b>5300 Memorial Drive, Suite 950</b></ix:nonNumeric>, <ix:nonNumeric contextRef="d20228K" name="dei:EntityAddressCityOrTown"><b>Houston</b></ix:nonNumeric>, <ix:nonNumeric contextRef="d20228K" name="dei:EntityAddressStateOrProvince"><b>TX</b></ix:nonNumeric> <ix:nonNumeric contextRef="d20228K" name="dei:EntityAddressPostalZipCode"><b>77007</b></ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Address of principal executive offices and zip code)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(<ix:nonNumeric contextRef="d20228K" name="dei:CityAreaCode"><b>713</b></ix:nonNumeric>) <ix:nonNumeric contextRef="d20228K" name="dei:LocalPhoneNumber"><b>300-5160</b></ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Former name or former address, if changed from last report)</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see </i>General Instruction A.2. below):</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:bottom;width:4.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric>&#xa0;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:4.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric>&#xa0;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:4.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric>&#xa0;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:4.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric>&#xa0;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; Emerging growth company&#xa0;<ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#xa0;&#9744;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-color: rgb(0, 0, 0); border-style: solid; border-width: 1px; vertical-align: bottom; width: 16.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title of each class</b></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 13%; border-top: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Trading Symbol (s)</b></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 16.7%; border-top: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of each exchange on which registered</b></div>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 16.7%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:Security12bTitle">Common Stock</ix:nonNumeric>, par value $.001 per share</div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 13%; border-right: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:TradingSymbol">MBRX</ix:nonNumeric></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 16.7%; border-right: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The <ix:nonNumeric contextRef="d20228K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric> Stock Market LLC</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#xa0;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">&#xa0;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item 7.01 </b></div>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Regulation FD Disclosure</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">On July 28, 2022, Moleculin Biotech, Inc. (the &#8220;Company&#8221;), issued a press release announcing it has completed the safety review of the fourth cohort in a dose escalation clinical trial evaluating&#xa0;Annamycin&#xa0;for the treatment of soft tissue sarcoma (STS) lung metastases, thus concluding the Phase 1b portion of its U.S. Phase&#xa0;1b/2 clinical trial. Preliminary results from the study continue to document clinical activity for Annamycin in the treatment of STS. The safety review committee (SRC) has deemed the dose of 390 mg/m<span style="font-size:7pt;"><sup>2</sup></span> to be safe after conclusion of the fourth cohort. Notwithstanding that there was safety at this dose level, tolerability issues present at the 390 mg/m<span style="font-size:7pt;"><sup>2</sup></span> dose level caused delays in follow-on cycles and the reduction of subsequent doses, suggesting that a Recommended Phase 2 Dose (RP2D) below 390 mg/m<span style="font-size:7pt;"><sup>2</sup></span> was warranted.</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be &#8220;filed&#8221; for the purpose of the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (&#8220;Securities Act&#8221;), unless specifically identified therein as being incorporated by reference.</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item 9.01 </b></div>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Financial Statements and Exhibits.</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; font-size: 10pt;">(d)</div>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; font-size: 10pt;">Exhibits.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Exhibit No.</b></div>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Description</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">99.1</div>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_400164.htm" style="-sec-extract:exhibit;">Press Release dated July 28, 2022</a></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">104</div>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Cover page Interactive Data File (formatted as Inline XBRL document)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><span style="text-decoration: underline;">SIGNATURE</span></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:54pt;">Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 50%;">&#xa0;</td>
			<td colspan="2" style="vertical-align: top; width: 3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>MOLECULIN BIOTECH, INC.</b>&#xa0;</div>
			</td>
			<td style="vertical-align: top; width: 12%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&#xa0;</td>
			<td style="vertical-align: top; width: 3%;">&#xa0;</td>
			<td style="vertical-align: top; width: 35%;">&#xa0;</td>
			<td style="vertical-align: top; width: 12%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&#xa0;</td>
			<td style="vertical-align: top; width: 3%;">&#xa0;</td>
			<td style="vertical-align: bottom; width: 35%;">&#xa0;</td>
			<td style="vertical-align: top; width: 12%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&#xa0;</td>
			<td style="vertical-align: top; width: 3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date:</div>
			</td>
			<td style="vertical-align: bottom; width: 35%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;July 28, 2022</div>
			</td>
			<td style="vertical-align: top; width: 12%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&#xa0;</td>
			<td style="vertical-align: top; width: 3%;">&#xa0;</td>
			<td style="vertical-align: bottom; width: 35%;">&#xa0;</td>
			<td style="vertical-align: top; width: 12%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&#xa0;</td>
			<td style="vertical-align: top; width: 3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 35%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/&#xa0;Jonathan P. Foster</div>
			</td>
			<td style="vertical-align: top; width: 12%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&#xa0;</td>
			<td style="vertical-align: top; width: 3%;">&#xa0;</td>
			<td style="vertical-align: top; width: 35%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Jonathan P. Foster</div>
			</td>
			<td style="vertical-align: top; width: 12%;">&#xa0;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_400164.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_400164.htm</title>
	<!-- Generated by ThunderDome Portal - 7/28/2022 12:44:09 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<div><img alt="logo.jpg" src="logo.jpg"></div>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>Moleculin Concludes Phase 1b and Opens Recruitment in Phase 2 Clinical Trial of</b></p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><i>&#8211; Preliminary Phase 1b data demonstrated clinical activity, defined as stable disease or better</i></p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><i>&#8211; Company determines RP2D to be 360 mg/m</i><i><sup>2</sup></i><i> and will begin Phase 2 recruitment </i></p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><i>&#8211; Annamycin has Fast Track Status and Orphan Drug Designation from FDA for the treatment of soft tissue sarcoma </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>HOUSTON,</b>&nbsp;<b>July 28, 2022</b>&nbsp;&#8212;&nbsp;<b>Moleculin Biotech, Inc.</b>, (Nasdaq: MBRX) (&#8220;Moleculin&#8221; or the &#8220;Company&#8221;), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced it has completed the safety review of the fourth cohort in a dose escalation clinical trial evaluating&nbsp;Annamycin&nbsp;for the treatment of soft tissue sarcoma (STS) lung metastases, thus concluding the Phase 1b portion of its U.S. Phase&nbsp;1b/2 clinical trial. Preliminary results from the study continue to document clinical activity for Annamycin in the treatment of STS. The safety review committee (SRC) has deemed the dose of 390 mg/m<font style="font-size:7pt;"><sup>2</sup></font> to be safe after conclusion of the fourth cohort. Notwithstanding that there was safety at this dose level, tolerability issues present at the 390 mg/m<font style="font-size:7pt;"><sup>2</sup></font> dose level caused delays in follow-on cycles and the reduction of subsequent doses, suggesting that a Recommended Phase 2 Dose (RP2D) below 390 mg/m<font style="font-size:7pt;"><sup>2</sup></font> was warranted.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">With this in mind and with the recommendation of the SRC, the Company has determined that the RP2D will be 360 mg/m<font style="font-size:7pt;"><sup>2</sup></font> for the first three subjects in the Phase 2 portion of the study. The SRC will then review the clinical safety data at this dose and determine whether the RP2D should be further reduced to 330 mg/m<sup><font style="font-size:7pt;">2</font> </sup>prior to proceeding with the additional 22 subjects. In addition to continuing to assess safety, including gathering additional information about short-term side effects and possible risks, this Phase 2 portion of the study will also explore the efficacy of Annamycin as a single agent for the treatment of subjects with STS lung metastases for whom prior chemotherapy has failed, and for whom new chemotherapy is considered appropriate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In the Phase 1b portion of the study, 15 subjects were enrolled and treated per the protocol in four cohorts to determine the maximum tolerable dose and/or the RP2D. Each cohort had three subjects, except for the fourth cohort, which (per the protocol) was expanded to six subjects after a dose-limiting toxicity (DLT) occurred in a single subject. The Company concluded the Phase 1b portion after the fourth cohort of 390 mg/m<font style="font-size:7pt;"><sup>2</sup></font> was documented to be safe. Up to 28 subjects, to account for potential over enrollment, will be enrolled at the RP2D in Phase 2 to focus more on quantifying efficacy as well as providing additional safety information.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8220;As we end the Phase 1b portion of this trial, the preliminary data continue to be encouraging,&#8221; said Moleculin Chairman and CEO Walter Klemp. &#8220;Of the fifteen subjects treated per the protocol, two continue with treatment, and eight subjects have been followed without evidence of disease progression for two months or greater, with three of the eight free of disease progression for 120 days or more. These data are early-stage, and we look forward to developing confirmatory data from future studies. However, based on the data available thus far, we believe Annamycin has the potential to bring a new and effective treatment option to patients with significant unmet needs,&#8221; Klemp said.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Mr. Klemp added, &#8220;We&#8217;re also encouraged by the pace of recruitment to date for this trial. To have completed the Phase 1b in just over one year was faster than we expected, especially for a rare disease like STS lung metastases. This is encouraging as we open the Phase 2 portion of the study.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The summary of interim Phase 1b data, which are preliminary and subject to change, from the four cohorts of the study are as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><u>First Cohort (210 mg/m</u></b><b><u><sup>2</sup></u></b><b><u>):</u></b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Two subjects received 6 cycles of Annamycin, initially having stable disease, and were then discontinued due to progressive disease.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">One subject received 1 cycle, but then discontinued from the study because of a Dosing Delay greater than the time between doses permitted by the protocol.&nbsp;At the End of Study scan performed 39 days post initiation of treatment, the subject had stable disease. The subject was followed and continued to exhibit disease free progression up to 61 days after treatment, at which point the subject began a different therapy.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><u>Second Cohort (270 mg/m</u></b><b><u><sup>2</sup></u></b><b><u>):</u></b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In one subject, the end of cycle 2 scan showed a partial response (&#8805;30% reduction in tumor size), and when scanned at the end of cycle 4 the subject showed stable disease. The subject subsequently discontinued from the study, electing to undergo surgical resection to potentially eradicate the disease.&nbsp;The subject is continuing to be followed and at the last follow-up no disease progression was reported at 272 days.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">One subject was discontinued from the study when the end of cycle 2 scan revealed progressive disease.&nbsp;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">One subject received 1 cycle of treatment and discontinued treatment due to a Dosing Delay. The End of Study scan revealed progressive disease.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><u>Third Cohort (330 mg/m</u></b><b><u><sup>2</sup></u></b><b><u>):</u></b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">One subject received 1 cycle and was discontinued when an interim, unscheduled scan revealed progressive disease.&nbsp;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">One subject was discontinued from the study when the end of cycle 2 scan revealed progressive disease.&nbsp;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">One subject was treated with 2 cycles and the end of cycle 2 scan revealed stable disease. The subjected elected to withdraw from receiving any further treatment. The subject was followed and no disease progression was reported at 146 days. The subject elected at that time to discontinue from further follow-up in the study.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><u>Fourth Cohort (390 mg/m</u></b><b><u><sup>2</sup></u></b><b><u>):</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Efficacy data for this cohort are incomplete as not all subjects have received their scans and treatment is ongoing.</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">One subject received 3 cycles of treatment without evidence of any DLTs, with the last 2 cycles at a reduced dose of 292 mg/m<sup>2</sup>&nbsp;due to a drug tolerability issue that did not qualify as a DLT. The subject exhibited stable disease at the end of cycle 2. The subject showed progressive disease in the end of treatment scan on the 78<sup>th</sup>&nbsp;day.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">One subject was discontinued from the study after 2 cycles with cycle 2 administered at a reduced dose of 292 mg/m<sup>2</sup>. The subject discontinued receiving cycles because of a DLT of febrile neutropenia, and the cohort was expanded per the protocol. The end of cycle 2 scan revealed stable disease. The subject initiated additional therapy unrelated to the study on the 68<sup>th</sup>&nbsp;day and will continue to be followed for Overall Survival.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">One subject received 3 cycles of treatment without evidence of any DLTs, with the last 2 cycles administered at reduced doses, due to drug tolerability. The subject exhibited stable disease at the end of cycle 2. The subject showed progressive disease in an unscheduled scan on the 79<sup>th</sup>&nbsp;day.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">One subject received 4 cycles without evidence of any DLTs, with the last three cycles administered at a reduced dose of 292 mg/m<sup>2</sup>, due to drug tolerability. The end of cycle 4 scans revealed stable disease. The subject is ongoing in the study.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">One subject received 3 cycles without evidence of any DLTs, with the last two cycles administered at a reduced dose of 292 mg/m<sup>2</sup>, due to drug tolerability. The end of cycle 2 scans revealed stable disease. The subject is ongoing in the study.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">One subject received 1 cycle without evidence of any dose-limiting toxicities and is ongoing in the study.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">One subject received a markedly lower dose than the specified 390 mg/m<sup>2</sup>&nbsp;in a protocol violation by the site, also without evidence of any DLTs. That subject&#8217;s safety data, but not efficacy, is deemed to be evaluable in the study.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8220;Consistent with our earlier and ongoing acute myeloid leukemia trials, in the subjects evaluated to date we have seen a complete absence of cardiotoxicity in our trials,&#8221; Mr. Klemp said. &#8220;Again, these are early-stage data, but we&#8217;re seeing consistent results in this regard across our Annamycin studies, and we think they&#8217;re important because, even though anthracyclines are considered a cornerstone chemotherapy for many types of cancer including STS lung metastases, all currently approved anthracyclines are significantly cardiotoxic. Annamycin was designed to overcome this problem and we believe it has the potential to become the first non-cardiotoxic anthracycline approved for use. If these data continue and our product is approved, Annamycin may not only reduce the risk of many current anthracycline treatment regimens, but it could also enable longer treatment periods with reduced concern for cardiac risk.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Annamycin currently has Fast Track Status and Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of soft tissue sarcoma, in addition to Orphan Drug Designation for the treatment of relapsed or refractory acute myeloid leukemia. For more information about the Phase&nbsp;1b/2 study evaluating Annamycin for the treatment of STS lung metastases, please visit&nbsp;clinicaltrials.gov&nbsp;and reference identifier NCT04887298.&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><u>Study Design</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In Phase&nbsp;1b, Annamycin was administered as an intravenous (IV) infusion over 2 hours on Day 1, followed by 20 days off (1 cycle = 21 days). Subjects visit the study site every 21 days (&#177;3 days) at which time safety monitoring &#8211; including for adverse events (AEs), as well as a physical examination, laboratory evaluations (clinical chemistry, complete blood count), vital signs, weight measurements, Eastern Cooperative Oncology Group (ECOG) performance status, and electrocardiograms (ECGs) &#8211; is performed, followed by an IV infusion of study drug. Cardiac function is followed by echocardiogram (ECHO) scans at screening, at the end of the first two cycles and then following every other cycle thereafter, at the End of Treatment visit, and if feasible, during follow up at 6 months (&#177;1 month) and 1 year (&#177;1 month) after study drug discontinuation. As long as the Investigator considers that the benefits of treatment with Annamycin continue to outweigh the risks, treatment will continue every 21 days until tumor progression is observed or unacceptable toxicity occurs.&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Tumor response is monitored every 6 weeks (&#177;1 week) from Cycle 1 Day 1 during treatment, at the End of Treatment visit, and then every 3 months (&#177;1 month) until disease progression using RECIST 1.1 criteria. Those subjects who leave the study after a maximum response is achieved and who do not start another therapy will be followed every 3 months (&#177;1 month) for progression-free survival (PFS). If a subject receives further therapy after discontinuing from the study, they will be followed only for overall survival (OS) and if feasible, follow-up ECHO scans at 6 months (&#177;1 month) and 1 year (&#177;1 month) will be conducted after study drug discontinuation.&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>About Annamycin</b>&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Annamycin is the Company&#8217;s next-generation anthracycline that has been shown in animal models to accumulate in the lungs at up to 30-fold the level of doxorubicin. Importantly, Annamycin has also demonstrated a lack of cardiotoxicity in multiple early-stage human clinical trials, including ongoing trials for the treatment of acute myeloid leukemia (AML) and STS lung metastases. For that reason, although additional data will be necessary, the Company believes Annamycin may not face the same usage limitations imposed on doxorubicin, one of the most common currently approved anthracyclines. Annamycin is currently in development for the treatment of AML and STS lung metastases and the Company believes the drug may have the potential to treat additional indications.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>About Moleculin Biotech, Inc. </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The Company&#8217;s lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of COVID-19 and other viruses, as well as cancer indications including brain tumors, pancreatic and other cancers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For more information about the Company, please visit&nbsp;www.moleculin.com&nbsp;and connect on&nbsp;Twitter,&nbsp;LinkedIn&nbsp;and&nbsp;Facebook.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Forward-Looking Statements </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation the final determination of the RP2D, the ability of Annamycin to demonstrate safety and efficacy in subjects, and the ability of the STS lung metastases clinical trial to continue the recruitment of subjects and the ability of Annamycin to eventually be approved by the FDA. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including &#8216;believes,&#8217; &#8216;estimates,&#8217; &#8216;anticipates,&#8217; &#8216;expects,&#8217; &#8216;plans,&#8217; &#8216;projects,&#8217; &#8216;intends,&#8217; &#8216;potential,&#8217; &#8216;may,&#8217; &#8216;could,&#8217; &#8216;might,&#8217; &#8216;will,&#8217; &#8216;should,&#8217; &#8216;approximately&#8217; or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. &#8220;Risk Factors&#8221; in our most recently filed Form 10-K filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Investor Contact:</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">JTC Team, LLC</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Jenene Thomas</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(833) 475-8247</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">MBRX@jtcir.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">SOURCE Moleculin Biotech, Inc.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>mbrx-20220728.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 7/28/2022 12:34:13 AM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:mbrx="http://www.mbrx.com/20220728" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.mbrx.com/20220728">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20220728_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20220728_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20220728_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.mbrx.com/20220728/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="mbrx_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>mbrx-20220728_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 7/28/2022 12:34:13 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.mbrx.com/20220728/role/statement-document-and-entity-information" xlink:href="mbrx-20220728.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.mbrx.com/20220728/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>mbrx-20220728_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 7/28/2022 12:34:13 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>mbrx-20220728_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 7/28/2022 12:34:13 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.mbrx.com/20220728/role/statement-document-and-entity-information" xlink:href="mbrx-20220728.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.mbrx.com/20220728/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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MM9<CD9]#Q^5,\*>!=%\&+<?V+%('N2/,DF?<Q Z#/IS714C,J(6=@JJ,DDX
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MGS/MNK+]" 7=UXGTNW_L6TDMK:T 96N5V%Y5&%4#T4G)/J !76VT"6UM'#&
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+ %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139970257290336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">MOLECULIN BIOTECH, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Jul. 28,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">001-37758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">47-4671997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">5300 Memorial Drive, Suite 950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">77007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">300-5160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MBRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0001659617<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>mbrx20220726_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mbrx-20220728.xsd" xlink:type="simple"/>
    <context id="d20228K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-07-28</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20228K">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20228K">0001659617</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20228K">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20228K">2022-07-28</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20228K">MOLECULIN BIOTECH, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20228K">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20228K">001-37758</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20228K">47-4671997</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20228K">5300 Memorial Drive, Suite 950</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d20228K">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20228K">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20228K">77007</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20228K">713</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20228K">300-5160</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20228K">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20228K">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20228K">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20228K">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="d20228K">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle contextRef="d20228K">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20228K">MBRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20228K">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MFY]N& 5;L /@]Y64YGAA=[;%/R:&_P%02P,$%     @ :$3\5)^@&_"Q @
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M\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @
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M-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U
M.EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*
M$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87
M_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( &A$_%0'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ :$3\5"EF2#OO    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ :$3\5)E<G",0!@  G"<  !,
M         ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !H
M1/Q4P0IL-DX$  "D$   &               @($."   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ :$3\5)^@&_"Q @  X@P   T
M         ( !D@P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !H1/Q4EXJ[
M',     3 @  "P              @ %N#P  7W)E;',O+G)E;'-02P$"% ,4
M    " !H1/Q4.JJBYT !   \ @  #P              @ %7$   >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ :$3\5"0>FZ*M    ^ $  !H
M     ( !Q!$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ :$3\5&60>9(9 0  SP,  !,              ( !J1(  %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  \Q,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="mbrx20220726_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mbrx.com/20220728/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="mbrx20220726_8k.htm">mbrx20220726_8k.htm</File>
    <File>ex_400164.htm</File>
    <File>mbrx-20220728.xsd</File>
    <File>mbrx-20220728_def.xml</File>
    <File>mbrx-20220728_lab.xml</File>
    <File>mbrx-20220728_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>logo.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mbrx20220726_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "mbrx-20220728_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mbrx20220726_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mbrx-20220728_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mbrx-20220728_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mbrx-20220728.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 26,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "mbrx",
   "nsuri": "http://www.mbrx.com/20220728",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbrx20220726_8k.htm",
      "contextRef": "d20228K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.mbrx.com/20220728/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbrx20220726_8k.htm",
      "contextRef": "d20228K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220728/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220728/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220728/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document, Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220728/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document, Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220728/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity, Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220728/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity, Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220728/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity, Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220728/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity, Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220728/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity, Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220728/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220728/role/statement-document-and-entity-information"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity, Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220728/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity, File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220728/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity, Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220728/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity, Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220728/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity, Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220728/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220728/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220728/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220728/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220728/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220728/role/statement-document-and-entity-information"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220728/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220728/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220728/role/statement-document-and-entity-information"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220728/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001437749-22-017952-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-22-017952-xbrl.zip
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M_OW>]LX>SSIV\S3R'J))S+-K?CW47?!4"4>66X+%Y=>BN4+K!0>T$#Q]A1K
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M4Z\?@6M_P-1"&)1@H,M9<MJ,-T+X .R)>"R\D8X<O0^8H4FP(#$\47"FTI/
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M8I!+7]\%$ZT@C"@NM)CAN^>5&Y?W@='U>ILT.@FL,%0BQ0^Y$CG@!*.V0/1
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M$EG*F!D[8\\Z@T%DYN?[/<_VQ_.<\_R^UWW>Y]SG7-?]^=RO^WV=^Z:,4>:
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M@,XT)&$] YK@O]T:YM$M2-,P"Y=$F>PNX++*UF98ZV1=?^'S7U!+ P04
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MLP&+3X&-!,;9N;^,;BS"Y6C$5P=L!O_D9X.KT!WHMW,5V[RXN/#5Z"HT);I
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M7#5V"UJD>)$@KJ&E,\D(I?79\</&2=R+K9OU+I+]'ZS8\Q]02P,$%     @
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MNK&9"M;@8HYM--OA >WOX:HTD<<*I^#WX:[P"#UK>MW6V.CFYB;4I4=H3HN
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M)@DV_/O3L43]J'\0XYU_ 5!+ P04    " !H1/Q42AX%C)<0  #1:P  $P
M &UB<G@R,#(R,#<R-E\X:RYH=&WM/6ES&DF6G\<1^Q_>TM,]*$*<0A>2B<"
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M4LHCJ,P!E /--H2A#*[UB"0RH32(*7#Y *MBLY]@8TYQ-\Z.E@(.OBT=[NQ
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M)O5+9W9?"P,>THCH\Z35NUG)6BX_)(Z6=4MEWE_+KM\T^\Y:\V%V@U[?\V+
MJHM]2"H*JA"I?^ SC?D57.;A)*!K/W\U&WA<QC\2OY^ZDHWN 9S6N[W<XB+"
MRDV'DUYGZ=UHD)/!]>I+RG7!7HU8>V%@Z?H _A*13__+E-K_ U!+ 0(4 Q0
M   ( &A$_%08UMG0+1D  /%^   -              "  0    !E>%\T,# Q
M-C0N:'1M4$L! A0#%     @ :$3\5.BY?OMA%   JA4   @
M ( !6!D  &QO9V\N:G!G4$L! A0#%     @ :$3\5)Z0O?-\ P  , X  !$
M             ( !WRT  &UB<G@M,C R,C W,C@N>'-D4$L! A0#%     @
M:$3\5-@&VT7=!   4BT  !4              ( !BC$  &UB<G@M,C R,C W
M,CA?9&5F+GAM;%!+ 0(4 Q0    ( &A$_%13'Z5Q^P4  *P\   5
M      "  9HV  !M8G)X+3(P,C(P-S(X7VQA8BYX;6Q02P$"% ,4    " !H
M1/Q4>E=YBGD$  #F+0  %0              @ '(/   ;6)R>"TR,#(R,#<R
M.%]P<F4N>&UL4$L! A0#%     @ :$3\5$H>!8R7$   T6L  !,
M     ( !=$$  &UB<G@R,#(R,#<R-E\X:RYH=&U02P4&      < !P"Z 0
&/%(

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
